Home › Trial NCT01200589
Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy
- Trial IDNCT01200589
- StatusTerminated
- PhasePhase 3
- Study typeInterventional
- SponsorNovartis Pharmaceuticals
- Enrollment438
- Start date2010-10-11
- ConditionsNon-Hodgkin's Lymphoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.